Bryant Furlow

Optimizing radiotherapy to spare muscles and nerves involved in swallowing from irradiation improves the risk of treatment-related dysphagia and patients’ quality of life.

This review of computed tomography texture analysis shows its potential for monitoring treatment responses and tumor evolution over time, particularly in renal cell carcinoma.

Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.

New research identifies the skin bacterium S. aureus as a likely culprit in high-grade acute radiation dermatitis, and indicates that topical antibiotics can prevent severe cases.

Sacituzumab govitecan improves outcomes vs physician’s choice of treatment in patients with endocrine-resistant, HR+, HER2- metastatic breast cancer, results from the phase 3 TROPiCS-02 study suggest.

Adding the mRNA-4157 vaccine to pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk, resected melanoma in a phase 2 trial.

Curative surgery for non-small cell lung cancer after treatment with nivolumab plus relatlimab is as safe as surgery after nivolumab alone, the NEOpredict-Lung study suggests.

If approved, vorasidenib could become a new standard of care for low-grade IDH1/2-mutated gliomas, according to an ASCO discussant.

The ADAURA trial is the first global phase 3 study to show an overall survival benefit with targeted treatment in resected, EGFR-mutated, stage IB-IIIA non-small-cell lung cancer, according to study presenter Roy S. Herbst, MD, PhD.

FLASH-RT can offer better tumor cell-killing efficacy, but a better understanding of the molecular responses and optimal dose rates are needed.